Women who were obese at diagnosis of hormone receptor-positive operable breast cancer that was treated with standard chemohormonal therapy had outcomes inferior to those of their nonobese counterparts in an ECOG-led study, the results of which were published early online August 27, 2012 in CANCER, a peer-reviewed journal of the American Cancer Society. The results had been previously presented in part at the San Antonio Breast Cancer Symposium on December 10, 2010 in San Antonio, TX. The analysis drew upon biospecimens contributed by women who had participated in E1199, E5188, and E3189.
“We’ve had a very tumor-centric view of treating cancer and haven’t paid much attention to how characteristics of the patient influence prognosis. Considering factors specific to the patient, such as obesity, and to the tumor, such as breast cancer subtype, could help us better identify those at risk of recurrence,” says lead study investigator Joseph Sparano, MD, Albert Einstein College of Medicine, Montefiore Medical Center (Bronx, New York) and Therapeutics Co-Chair of the ECOG-ACRIN Breast Committee. “We found a pretty striking relationship between obesity and recurrence of a common breast cancer subtype, which we think may eventually lead to testing new strategies to prevent recurrence.”
Complete author list: Joseph A. Sparano, Molin Wang, Fengmin Zhao, Vered Stearns, Silvana Martino, Jennifer A. Ligibel, Edith A. Perez, Tom Saphner, Antonio C. Wolff, George W. Sledge, Jr., William C. Wood, John Fetting, and Nancy E. Davidson.
Citation: Sparano JA, Wang M, Zhao F, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer; published online August 27, 2012; doi: 10.1002/cncr.27527.